Hikma to Buy Boehringer Ingelheim’s Roxane for $2.65 Billion

Updated on

Hikma Pharmaceuticals Plc agreed to buy Boehringer Ingelheim GmbH’s Roxane business for $2.65 billion in cash and stock to become the sixth-largest supplier of generic medicines in the U.S.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.